The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon

Cancer Journal from Scientific American

Volumn 4, Issue 3, 1998, Pages 162-167

  Small, Eric J ^a,i   Weiss, Geoffrey R ^b   Malik, Umme K ^c   Walther, Philip J ^d   Johnson, David ^e   Wilding, George ^f   Kuzel, Timothy ^g   Bajamonde, Alex ^h   Paton, Virginia ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WISCONSIN   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h GENENTECH INC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gamma interferon; Prognostic variables; Renal cell carcinoma

Indexed keywords

RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA, RECOMBINANT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0031804783     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parker SL, Tong T, Bolden S et al. Cancer statistics, 1997. CA Cancer J Clin 1996;47:5-27.
2. Ritchie AW, Chisholm GD. The natural history of renal carcinoma. Semin Oncol 1983;10:390-400.
3. Yagoda A, Bassam AR, Petrylak D. Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
4. Parkinson DR, Sznol M. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma. Semin Oncol 1995;22:61-6.
5. Stadler WM, Vogelzang NJ. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol 1995;22:67-73.
6. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma. Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Cancer 1987;60:929-933.
7. Bruntsch U, deMulder PHM, ten Bokkel Huinink WW et al. Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma. J Biol Response Mod 1990;9:335-338.
8. Foon KA, Sherwin SA, Abrams PG et al. A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother 1985;20:193-197.
9. Garnick MB, Riech SD, Maxwell B et al. Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. J Urol 1988;139:251-255.
10. Grups JW, Frohmuller HG. Cyclic interferon gamma treatment of patients with metastatic renal cell carcinoma. Br J Urol 1989; 64:218-220.
11. Kuebler JP, Goodman PJ, Brown TD et al. Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. Invest New Drugs 1990;8:307-309.
12. Quesada JR, Kurzrock R, Sherwin S et al. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod 1987;6:20-27.
13. Aulitzky WE, Lerche J, Thews A et al. Low-dose γ-interferon therapy is ineffective in renal cell carcinoma patients with large tumor burden. Eur J Cancer 1994;30:940-945.
14. Ellerhorst JA, Kilbourn RG, Amato RJ et al. Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma. J Urol 1994; 152:841-845.
15. Fleiss LJ. The Design and Analysis of Clinical Experiments (vol 14). New York: John Wiley & Sons, 1986.
16. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376-379.
17. Golimbu M, Joshi P, Sperber A et al. Renal cell carcinoma: survival and prognostic factors. Urology 1986;27:291-301.
18. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-7313.
19. Mani S, Todd MB, Katz K et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995;154:35-40.
20. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who receive high dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-696.
21. Canobbio L, Rubagotti A, Miglietta L et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha. J Cancer Res Clin Oncol 1995;121:753-756.
22. Landonio G, Baiocchi C, Cattaneo D et al. Retrospective analysis of 156 cases of metastatic renal cell carcinoma: evaluation of prognostic factors and response to different treatments. Tumori 1994; 80:468-472.
23. Lissoni P, Barni S, Ardizzoia A et al. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 1994;51:59-62.
24. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994;30A:1310-1314.
25. Minisian LM, Motzer RJ, Gluck L et al. Interferon alpha 2-a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993;11: 1368-1375.
26. Palmer PA, Vinke J, Philip T et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475-480.
27. Hanninen EL, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996;155: 19-25.